| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
Cell lines | ECSCs and NESCs |
Preparation method | The solubility of this compound in DMSO is >12.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months. |
Reacting condition | 0.01 ~ 10 μM; |
Applications | In ECSCs and NESCs, BAY 11-7085 significantly inhibited cell viability in a dose-dependent manner. At the dose of 10 μM, ECSCs and NESCs treated with BAY 11-7085 showed 66.1% and 54.7% decreases in cell viability, respectively. In addition, according to the results of the BrdU incorporation assay, at the dose of 10 μM, BAY 11-7085 significantly inhibited the BrdU incorporation of ECSCs in a dose-dependent manner (53.2% decrease), whereas BAY 11-7085 only showed a weak inhibitory effect on the BrdU incorporation of NESCs (38.2% decrease). Therefore, BAY 11-7085 showed stronger inhibitory effects on the cell viability and the cell proliferation of ECSCs than on those of NESCs. |
Animal models | Rat model of pneumococcal meningitis |
Dosage form | 20 mg; i.p. |
Applications | In rat model of pneumococcal meningitis, BAY 11-7085 significantly reduced meningitis-associated loss of cerebrovascular autoregulation. Besides, also BAY 11-7085 also significantly reduced increases in CSF WBCs, ICP and BBB permeability caused by pneumococcal infection. The results of Western blot analysis showed BAY 11-7085 inhibited meningitis-associated increase in NF-κB activity. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 文献引用 | |
| 产品描述 | BAY 11-7085 is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM. BAY 11-7085 inhibits TNFa-induced surface expression of E-selectin, VCAM-1, and ICAM-1with IC50 values in the range of 5-10 μM. BAY 11-7085 stabilizes IκBα in a dose-dependent manner with an IC50 value of approximately 10 μM. There is a clear correlation between the concentration of drug that stabilized IκBα, the concentration that inhibits nuclear levels of NF-kB, and the concentration that inhibits adhesion molecule expression[1]. BAY 11-7085 has been shown to inhibit cell proliferation and induce apoptosis of a variety of cells. BAY 11-7085 (ECSCs) significantly inhibits the cell proliferation and DNA synthesis of ovarian endometriotic cyst stromal cells and induces apoptosis and the G0/G1 phase cell cycle arrest of these cells. BAY 11-7085 induces apoptosis of ECSCs by suppressing antiapoptotic proteins, and that caspase-3-, -8-, and -9-mediated cascades are involved in this mechanism[2]. BAY 11-7085 acts as an anti-inflammatory agent in both the rat carrageenan paw and the rat adjuvant arthritis model. It demonstrates a dose-dependent reduction in swelling in the rat carrageenan paw model[1]. References: |
m.cnreagent.com